Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2016 by Dana-Farber Cancer Institute
Information provided by (Responsible Party):
Ursula A. Matulonis, MD, Dana-Farber Cancer Institute Identifier:
First received: June 7, 2012
Last updated: October 25, 2016
Last verified: October 2016
No Study Results Posted on for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2017
  Estimated Primary Completion Date: August 2017 (Final data collection date for primary outcome measure)